Amphastar Pharmaceuticals Retained Earnings (Accumulated Deficit) 2012-2024 | AMPH
Amphastar Pharmaceuticals retained earnings (accumulated deficit) from 2012 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Amphastar Pharmaceuticals Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$409 |
| 2022 |
$272 |
| 2021 |
$180 |
| 2020 |
$118 |
| 2019 |
$116 |
| 2018 |
$67 |
| 2017 |
$73 |
| 2016 |
$71 |
| 2015 |
$60 |
| 2014 |
$63 |
| 2013 |
$74 |
| 2012 |
$62 |
| 2011 |
$ |
| 2009 |
$71 |
Amphastar Pharmaceuticals Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-09-30 |
$531 |
| 2024-06-30 |
$490 |
| 2024-03-31 |
$452 |
| 2023-12-31 |
$409 |
| 2023-09-30 |
$373 |
| 2023-06-30 |
$324 |
| 2023-03-31 |
$298 |
| 2022-12-31 |
$272 |
| 2022-09-30 |
$238 |
| 2022-06-30 |
$222 |
| 2022-03-31 |
$205 |
| 2021-12-31 |
$180 |
| 2021-09-30 |
$161 |
| 2021-06-30 |
$131 |
| 2021-03-31 |
$123 |
| 2020-12-31 |
$118 |
| 2020-09-30 |
$124 |
| 2020-06-30 |
$120 |
| 2020-03-31 |
$120 |
| 2019-12-31 |
$116 |
| 2019-09-30 |
$117 |
| 2019-06-30 |
$116 |
| 2019-03-31 |
$68 |
| 2018-12-31 |
$67 |
| 2018-09-30 |
$66 |
| 2018-06-30 |
$67 |
| 2018-03-31 |
$70 |
| 2017-12-31 |
$73 |
| 2017-09-30 |
$75 |
| 2017-06-30 |
$75 |
| 2017-03-31 |
$73 |
| 2016-12-31 |
$71 |
| 2016-09-30 |
$74 |
| 2016-06-30 |
$70 |
| 2016-03-31 |
$63 |
| 2015-12-31 |
$60 |
| 2015-09-30 |
$53 |
| 2015-06-30 |
$56 |
| 2015-03-31 |
$62 |
| 2014-12-31 |
$63 |
| 2014-09-30 |
$66 |
| 2014-06-30 |
$71 |
| 2014-03-31 |
$72 |
| 2013-12-31 |
$74 |
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
$62 |
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.294B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
